AAP News Vol. 13 No. 9 September 1997, p. 13
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Flu-fighting intranasal spray vaccine shows potenial

A live-virus influenza vaccine, administered in a nasal spray, protected 93 percent of children vaccinated in a 10-site U.S. study conducted dufing the fall 1996 flu season.

Only I percent of the 1,070 children who received the vaccine developed culture-confirmed flu, compared to 18 percent of the 532 children who received a placebo. The vaccine protected children from both the A and B flu strains circulating last year.

The Phase 3, double-blind trial was conducted at 10 sites nationwide. Six sites were supported by the National Institute of Allergy and Infectious Diseases (NIAID), four by the biopharmnaceutical company Aviron, based at Mountain View, Calif.